









acting by direct selective inhibition of factor Xa.

- Apixaban may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apixaban does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional

thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.

• An agent to reverse the anti-factor Xa activity of apixaban is available.